sameAs
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary HyperhidrosisTriple in Asthma Dose FindingStudy of Efficacy and Safety of NVA237 in Patients With Poorly Controlled AsthmaSafety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic ConditionsComparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular BlockadeRandomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseEfficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator TiotropiumIntraoperative Video Laryngoscopy as Adjunct for Nerve MonitoringComparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn SurgeryEffect of Sugammadex vs. Neostigmine/Glycopyrrolate on Pediatric Emergence Delirium in Sevoflurane-rocuronium AnesthesiaEfficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic LavageThe Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary DiseaseEfficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary DiseaseRandomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and GlycopyrrolateThe Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in PatieResidual Neuromuscular Blockade in Cardiac Surgery PatientsEffects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRISugammadex Versus Neostigmine for Reversal of Rocuronium NeuromuscularEffect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Adult Patients Undergoing Lower Extremity Surgery Under Spinal AnesthesiaEffect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Geriatric Patients Undergoing Total Knee Replacement Under Spinal AnesthesiaChronotropic Incompetence in Patients With HFpEFEfficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD PatientsThe Use of Sugammadex in the Critically IllEfficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)Rates and Severity of PONV for Neuromuscular Block Reversal in Patients Receiving Gastric Bypass Bariatric SurgeryPharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy VolunteersInvestigation of Sugammadex in Outpatient Urological ProceduresSafety and Efficacy Study of Glyco pMDI After Single and Repeated AdministrationBiopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy VolunteersA Study to Assess the Long-term Safety of QVA149Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
P4844
Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysisClinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of lifeProfile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPDRole of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease.Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies
P921
Q61894460-27745D10-B479-4E19-8F77-A32FD06A678EQ61894598-FF9F8FD3-4D3F-4F49-935F-C1B0F8B12ADAQ61894614-A7B6A2C4-60B6-4D6C-A7E1-1B0447B8402CQ61917928-08CD4669-FB26-4693-88C8-AA0EF825A19AQ61920998-219A89BE-8E5F-4459-A01D-EAD612BE1369Q61966877-61FAC3AC-366F-41BC-9EFA-6929CB166695Q61969615-B5297FD8-59D3-4E86-BF67-0ED6876D9CEBQ61979207-2A55637F-78C5-48A2-8882-5D08E37AA6A9Q61980299-6C31BE1B-CEDA-4AB5-98D2-36C28A9FFB88Q62034779-5BAA9C89-33AE-4AE4-B148-9262A27323BAQ62819230-2D51115B-801F-44B4-8762-D3AC4C3E2FA9Q63012877-1C4998FB-EBE8-4EF2-97D3-9F31E06AFF76Q63062275-24BC9EEE-DC8C-4F14-81D8-50D7B954B5C4Q63315929-36342DD3-C2F1-459D-854B-9A3D1D588130Q63317387-ABEC6505-CF58-4B45-814B-FE274CFFA7F2Q63317761-33DB322B-7A3C-444A-997E-28CF4417BCC3Q63318303-30913229-5970-4F75-BD51-FF9041CAB6D9Q63320701-2C9D5AEA-8418-463D-A849-7852E072BD24Q63320905-BF55118C-A740-48DE-8269-4F90FB4FFF28Q63321913-F9417C43-DC64-4F48-A88E-BEF7A8A9D47DQ63338397-63034C97-4C54-4E6F-869D-FFFF24C48668Q63339334-34D0AFBE-B776-4284-A5CC-E3D5B5656C59Q63393744-7D2E8291-5AAA-4989-9F7C-F8423F589FC5Q63396980-09928AD2-337A-48EA-B92F-ABB522320F79Q63534501-7DAA85CB-4438-4A5E-9546-71441C6A1FC7Q63534706-52563998-29CB-4D45-93C6-D923FA442572Q63534773-C7B6D12A-128C-4E88-985A-6B495E03EC00Q63534778-BCF8AAE5-2CAB-4F3C-A842-87EF8F43D799Q63571320-4789BEA0-518D-42FB-BA24-FB5ADAE628EDQ63587383-E1B148D8-F599-4B29-A9B0-19AC0AE28303Q63593117-94A5EF68-B285-4312-ABBA-ED68B8681AF5Q63594623-B7B1FA86-BCA4-4FF1-8F3A-ED06ED640350Q63599729-CED12245-B78C-4A14-86ED-CEAAF694BC07Q63613573-73E726B9-AE52-4239-8374-1BFA98A49C5CQ63807563-8527D67C-7D55-4257-A7F4-F4F914FF9A2CQ63807749-AA715131-CA6C-4950-BCE0-5A2D06A534B8Q63829805-AFBEAE54-56C0-457D-8CB0-B8F710208CFDQ63829817-E615AF14-96B7-4AC3-9AAE-5CEF51166262Q63830204-C719470A-3659-4D47-99D7-929ADB44A814Q63830211-4C255621-0936-4697-AA41-CE0C4D641CB7
P4844
Q26782484-F9E7ED32-ED00-4141-9FE2-54C043AF5FCAQ26801134-029DA130-2375-467F-8089-671BE4DA7A57Q26825822-28DB3EFC-46AD-4FC8-898E-57B5C7FD44B7Q35541687-891DC63C-23B1-4565-BBD3-3F5946AB9D06Q37170227-5EE03D92-BA3A-41A3-95E2-452095EC4227Q38051307-774C8E5A-B8DB-4FEE-8CAE-11FBE2CE5243Q38057220-9A457DEB-3A6C-4E2B-98AE-C5F9A0450579Q38204363-35413DC4-2F4A-4D20-8048-216252008856Q47102804-5C808854-9E25-495E-A5F7-9B19B627E0A1Q64228030-7899A774-E6A9-40D9-8B4E-92B2B07492C4
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Bromek glikopironiowy
@pl
Glicopirrolato
@es
Glicopirronio bromuro
@it
Glikopirolat
@sr
Glikopironijum bromid
@sh
Glycopyrronium
@nl
Glycopyrroniumbromid
@de
Glykopyrroni
@fi
bromure de glycopyrronium
@fr
glicopirrolato
@pt
type
label
Bromek glikopironiowy
@pl
Glicopirrolato
@es
Glicopirronio bromuro
@it
Glikopirolat
@sr
Glikopironijum bromid
@sh
Glycopyrronium
@nl
Glycopyrroniumbromid
@de
Glykopyrroni
@fi
bromure de glycopyrronium
@fr
glicopirrolato
@pt
altLabel
AHR-504
@cy
AHR-504
@en
Gastrodyn
@fi
Glycopyrrolat
@de
Glykopyrrolaatti
@fi
Glykopyrronium
@fi
Glykopyrroniumbromidi
@fi
Robinul
@de
Robinul
@fi
Robinul®
@cy
prefLabel
Bromek glikopironiowy
@pl
Glicopirrolato
@es
Glicopirronio bromuro
@it
Glikopirolat
@sr
Glikopironijum bromid
@sh
Glycopyrronium
@nl
Glycopyrroniumbromid
@de
Glykopyrroni
@fi
bromure de glycopyrronium
@fr
glicopirrolato
@pt
P129
P2175
P672
P486
P592
P646
P661
P662
P683
P129
P2067
318.206919
P2115
N0000146747
P231
13283-82-4
P233
C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C
P234
1S/C19H28NO3/c1-20(2)13-12-17( ...... 6-17,22H,6-7,10-14H2,1-2H3/q+1
P235
ANGKOCUUWGHLCE-UHFFFAOYSA-N
P274
C₁₉H₂₈NO₃+